Log In or Create Account

Resistance Mutations
Podcasts
Key Slides
Question of the Week
CROI
RWHAP Clinical Conference
Donate
Contact

CME Courses
CME Webinars
Dialogues
Topics In Antiviral Medicine
Did You Know?
- FAQs
Fellow/Student Resources
About

Jason Baker, MD, MS, FIDSA

Jason Baker, MD, MS, FIDSA

Hennepin Healthcare

Professor of Medicine
Chief, Infectious Diseases

University of Minnesota
Hennepin Healthcare

131 Steuart St, Suite 500, San Francisco, CA 94105

Phone: (415) 544-9400 | info@iasusa.org

Home
Activities
Resources
About
Contact
Login
Careers
Donate
Website Policies

© 2023 International Antiviral Society–USA. All Rights Reserved.

Resistance Mutations
Podcasts
Key Slides
Question of the Week
CROI
RWHAP Clinical Conference
Donate
Contact
CME Courses
CME Webinars
Dialogues
Topics In Antiviral Medicine
Did You Know?
- FAQs
Fellow/Student Resources
About

Practice Question of the Week

September 18, 2023: Drug-Drug Interactions in Patients With HIV and Alcohol Use Disorder

A 34-year-old man presents to care after a recent hospital admission for acute alcohol intoxication, complicated by a fall and pneumonia. He is diagnosed with alcohol use disorder. He has an 8-year history of HIV, with an HIV RNA level of 3000 copies/mL and he reports difficulty adhering to his antiretroviral therapy. Which of the following is the most appropriate pharmacotherapy for his alcohol use disorder?
- A. Acamprosate, taken by mouth 3 times daily
- B. Disulfiram, taken by mouth daily
- C. Extended-release injectable naltrexone, administered every 4 weeks
- D. None of the above

Register for the Webinar

View Archived Questions